Clinical significance of serum concentration of anti-Müllerian hormone in obese women with polycystic ovary syndrome

Reproductive BioMedicine Online

Volumn 15, Issue 5, 2007, Pages 495-499

  El Halawaty, Samir ^a   Rizk, Ahmed ^b   Kamal, Manal ^c   AboulHassan, Mona ^c   Al Sawah, Heba ^a   Noah, Olfat ^a   Al Inany, Hesham ^a,d  

^a CAIRO UNIVERSITY   (Egypt)

^b BENHA UNIVERSITY   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

^d NONE   (Egypt)

Author keywords

Anti M llerian hormone; Clomiphene citrate; Obesity; Ovulation induction; Polycystic ovary syndrome

Indexed keywords

CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; ESTRADIOL; FOLLITROPIN; GLUCOSE; INSULIN; MUELLERIAN INHIBITING FACTOR;

ARTICLE; BODY MASS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREDICTION; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY;

EID: 36448943293     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)60379-3     Document Type: Article

References (20)

1. Barber TM, McCarthy MI, Wass JA, Franks S 2006 Obesity and polycystic ovary syndrome. Clinical Endocrinology 65, 137-145.
2. Ciaraldi TP, Morales AJ, Hickman MG et al. 1997 Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity. Journal of Clinical Endocrinology and Metabolism 82, 1421-1425.
3. Cook CL, Siow Y, Taylor S, Fallat ME 2000 Serum Müllerian inhibiting substance levels during normal menstrual cycles. Fertility and Sterility 73, 859-861.
4. Douchi T, Oki T, Yamasaki H et al. 2004 Body fat patterning in polycystic ovary syndrome women as a predictor of the response to clomiphene. Acta Obstetricia et Gynecologica Scandinavica 83, 838-841.
5. Fleming R 2005 Recruitment prior to ovarian stimulation: ways of improving follicular recruitment. Reproductive BioMedicine Online 10 (Suppl. 3), 55-59.
6. Ghobadi C, Nguyen TH, Lennard MS et al. 2007 Evaluation of an existing nomogram for predicting the response to clomiphene citrate. Fertility and Sterility 87, 597-602.
7. Imani B, Eijkemans MJ, te Velde ER et al. 2002 A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertility and Sterility 77, 91-97.
8. Imani B, Eijkemans MJ, te Velde ER et al. 1998 Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligomenorrheic infertility. Journal of Clinical Endocrinology and Metabolism 83, 2361-2365.
9. Johnson NP, Bagrie EM, Coomarasamy A et al. 2006 Ovarian reserve tests for predicting fertility outcomes for assisted reproductive technology: the International Systematic Collaboration of Ovarian Reserve Evaluation protocol for a systematic review of ovarian reserve test accuracy. BJOG 113 1472-1480.
10. Kousta E, White DM, Franks S 1997 Modem use of clomiphene citrate in induction of ovulation. Human Reproduction Update 3, 359-365.
11. Kwee J, Schats R, McDonnell J et al. 2006 The clomiphene citrate challenge test versus the exogenous follicle-stimulating hormone ovarian reserve test as a single test for identification of low responders and hyperresponders to in-vitro fertilization. Fertility and Sterility 85, 1714-1722.
12. Laven JS, Mulders AG, Visser JA et al. 2004 Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. Journal of Clinical Endocrinology and Metabolism 89, 318-323.
13. Lee MM, Donahoe PK, Hasegawa T et al. 1996 Müllerian inhibiting substance in humans: normal levels from infancy to adulthood. Journal of Clinical Endocrinology and Metabolism 81, 571-576.
14. Matthews DR, Rudenski AS, Naylor BA et al. 1985 Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419.
15. Mor E, Zograbyan A, Saadat P et al. 2004 The insulin resistant subphenotype of polycystic ovary syndrome: clinical parameters and pathogenesis. American Journal of Obstetrics and Gynecology 190, 1654-1660.
16. Pasquali R, Gambineri A 2006 Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age. Annals of the New York Academy of Sciences 1092, 158-174.
17. Salehi M, Bravo-Vera R, Sheikh A et al. 2004 Pathogenesis of polycystic ovary syndrome: what is the role of obesity? Metabolism 53, 358-376.
18. Seifer DB, MacLaughlin DT, Christian BP et al. 2002 Early follicular serum Müllerian inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertility and Sterility 77, 468-471.
19. Sozen I, Arici A 2000 Hyperinsulinism and its interaction with hyperandrogenism in polycystic ovary syndrome. Obstetrical and Gynecological Survey 55, 321-328.
20. Teixeira J, Maheswaran S, Donahoe PK 2001 Müllerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocrine Reviews 22, 657-674.